← Back to Search

Sequence A: VHX-896 then iloperidone for Schizophrenia

Phase 1
Waitlist Available
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 days
Awards & highlights
No Placebo-Only Group

Summary

Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.

Eligible Conditions
  • Schizophrenia
  • Bipolar Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Bioequivalence between VHX-896 tablets relative to iloperidone tablets
Secondary study objectives
Assessment of safety and tolerability of VHX-896 and iloperidone

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Sequence B: Iloperidone then VHX-896Experimental Treatment1 Intervention
Group II: Sequence A: VHX-896 then iloperidoneExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iloperidone and VHX-896
2021
Completed Phase 1
~30
VHX-896 and iloperidone
2021
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor
62 Previous Clinical Trials
19,406 Total Patients Enrolled
6 Trials studying Schizophrenia
1,470 Patients Enrolled for Schizophrenia
~16 spots leftby Nov 2025